SGLT2 inhibitors and cardiovascular outcomes in type 2 diabetes: VERTIS CV trial | GPnotebook TV

This site is intended for UK healthcare professionals

GPnotebook ↗︎
GPnotebook Podcast ↗︎
×
Sign in

SGLT2 inhibitors and cardiovascular outcomes in type 2 diabetes: VERTIS CV trial

29 July 2020
Dr Kevin Fernando summarises results from the cardiovascular outcomes trial of ertugliflozin presented at the American Diabetes Association’s 2020 congress, along with the implications for primary care.

Categories

Tags

The content of this website is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. Any distribution or duplication of the information contained herein is strictly prohibited.

© Oxbridge Solutions Ltd, 2023

 

Thanks for your feedback. Please note that by including your email address, you are giving permission for us to contact you by email to help resolve any issues.

Log in to track your activity and claim CPD credits

  • If you have registered for GPnotebook Pro, you can now automatically track the videos you watch on GPnotebook TV for CPD purposes
  • Simply log in to GPnotebook TV before watching any videos and your activity will be logged in your GPnotebook Pro dashboard
  • When the time is right, visit your GPnotebook Pro CPD dashboard to add reflections and claim CPD credits
  • A GPnotebook Pro account also provides access to exclusive videos 

Already registered for GPnotebook Pro?

×
Sign in

Not yet registered for GPnotebook Pro?

Learn more and register here

GPnotebook Pro is currently available to UK healthcare professionals only